References
1. Macy E, Poon K-YT. Self-reported antibiotic allergy incidence and prevalence: age and sex effects. Am J Med 2009;122:778.e1-e7.
2. Lieberman PL. Recognition and first-line treatment of anaphylaxis. Am J Med 2014;127(1 Suppl):S6-S11.
3. Renaudin JM, Beaudouin E, Ponvert C, et al. Severe drug-induced anaphylaxis: analysis of 333 cases recorded by the Allergy Vigilance Network from 2002 to 2010. Allergy 2013;68:929-937.
4. Kaushal R, Shojania KG, Bates DW. Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch Intern Med 2003;163:1409-1416.
5. Wolfstadt JI, Gurwitz JH, Field TS, et al. The effect of computerized physician order entry with clinical decision support on the rates of adverse drug events: a systematic review. J Gen Intern Med 2008;23:451-458.
6. Overhage JM, Gandhi TK, Hope C, et al. Ambulatory computerized prescribing and preventable adverse drug events. J Patient Saf 2016;12:69-74.
7. Weingart SN, Toth M, Sands DZ, et al. Physicians' decisions to override computerized drug alerts in primary care. Arch Intern Med 2003;163:2625-2631.
8. Jani YH, Barber N, Wong IC. Characteristics of clinical decision support alert overrides in an electronic prescribing system at a tertiary care paediatric hospital. Int J Pharm Pract 2011;19:363-366.
9. Nanji KC, Slight SP, Seger DL, et al. Overrides of medication-related clinical decision support alerts in outpatients. J Am Med Inform Assoc 2014;21:487-491.
10. Bryant AD, Fletcher GS, Payne TH. Drug interaction alert override rates in the Meaningful Use era: no evidence of progress. Appl Clin Inform 2014;5:802-813.
11. Hsieh TC, Kuperman GJ, Jaggi T, et al. Characteristics and consequences of drug allergy alert overrides in a computerized physician order entry system. J Am Med Inform Assoc 2004;11:482-491.
12. Joint Task Force on Practice Parameters American Academy of Allergy, Asthma and Immunology American College of Allergy, Asthma and Immunology. et al. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010;105:259-273.
13. Tilles SA, Slatore CG. Hypersensitivity reactions to non-beta-lactam antibiotics. Clin Rev Allergy Immunol 2003;24:221-228.
14. Araú L, Demoly P. Macrolides allergy. Curr Pharm Des 2008;14:2840-2862.
15. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003;349:1628-1635.
16. Apter AJ, Kinman JL, Bilker WB, et al. Is there cross-reactivity between penicillins and cephalosporins? Am J Med 2006;119:354.e11-e19.
17. Demoly P, Adkinson NF, Brockow K, et al. International consensus on drug allergy. Allergy 2014;69:420-437.
18. Romano A, Gaeta F, Valluzzi RL, et al. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of alternative cephalosporins. J Allergy Clin Immunol 2015;136:685-691.e3.
19. Dash CH. Penicillin allergy and the cephalosporins. J Antimicrob Chemother 1975;1(3 Suppl):107-118.
20. Petz LD. Immunologic cross-reactivity between penicillins and cephalosporins: a review. J Infect Dis 1978;137(Suppl):S74-S79.
21. Pichichero ME, Zagursky R. Penicillin and cephalosporin allergy. Ann Allergy Asthma Immunol 2014;112:404-412.
22. Lehmann DF. The metabolic rationale for a lack of cross-reactivity between sulfonamide antimicrobials and other sulfonamide-containing drugs. Drug Metab Lett 2012;6:129-133.
23. Ghimire S, Kyung E, Lee JH, et al. An evidence-based approach for providing cautionary recommendations to sulfonamide-allergic patients and determining cross-reactivity among sulfonamide-containing medications. J Clin Pharm Ther 2013;38:196-202.
24. Carrington DM, Earl HS, Sullivan TJ. Studies of human IgE to a sulfonamide determinant. J Allergy Clin Immunol 1987;79:442-447.
25. Ahmad A, Ramakrishnan A, McLean MA, et al. Use of optical biosensor technology to study immunological cross-reactivity between different sulfonamide drugs. Anal Biochem 2002;300:177-184.
26. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003;139:683-693.
27. Wulf NR, Matuszewski KA. Sulfonamide cross-reactivity: is there evidence to support broad cross-allergenicity? Am J Health Syst Pharm 2013;70:1483-1494.
28. Macy E, Ho NJ. Multiple drug intolerance syndrome: prevalence, clinical characteristics, and management. Ann Allergy Asthma Immunol 2012;108:88-93.
29. Omer HM, Hodson J, Thomas SK, et al. Multiple drug intolerance syndrome: a large-scale retrospective study. Drug Saf 2014;37:1037-1045.
30. Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin "allergy" in hospitalized patients: a cohort study. J Allergy Clin Immunol 2014;133:790-796.
31. Thornhill MH, Dayer MJ, Prendergast B, et al. Incidence and nature of adverse reactions to antibiotics used as endocarditis prophylaxis. J Antimicrob Chemother 2015;70:2382-2388.
32. Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs-an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013;68:702-712.
33. Macy E. Penicillin allergy: optimizing diagnostic protocols, public health implications, and future research needs. Curr Opin Allergy Clin Immunol 2015;15:308-313.